Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07) (NCT05555732)

🧪 Interventions in This Study

• Datopotamab Deruxtecan (DRUG)
• Pembrolizumab (DRUG)
• Pemetrexed (DRUG)
• Carboplatin (DRUG)
• Cisplatin (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (260 Sites)

Showing the first 25 of 260 sites.

• Southern Cancer Center Pc — Daphne, Alabama
• Ironwood Cancer and Research Centers — Chandler, Arizona
• Arizona Oncology Associates, Pc - Nahoa — Prescott Valley, Arizona
• Hoag Memorial Hospital Prebyterian — Newport Beach, California
• Compassionate Cancer Care Medical Group — Riverside, California
• Sansum Clinic — Santa Barbara, California
• Ronald Reagan UCLA Medical Center — Santa Monica, California
• UCHealth Memorial Hospital — Colorado Springs, Colorado
• Florida Cancer Specialists - South — Fort Myers, Florida
• Cancer Specialist of North Florida — Jacksonville, Florida
• Cancer Care Centers of Brevard, Inc. — Palm Bay, Florida
• Woodlands Medical Specialists, Pa — Pensacola, Florida
• Florida Cancer Specialists-North — St. Petersburg, Florida
• Emory University - Winship Cancer Institute Wci — Atlanta, Georgia
• Illinois Cancer Specialists — Niles, Illinois
• American Oncology Partners of Maryland — Bethesda, Maryland
• Maryland Oncology Heamtology P.A. — Columbia, Maryland
• Beth Israel Deaconess Medical Center — Boston, Massachusetts
• Dana Farber Cancer Institute; Inv Drg Svc Pharm — Boston, Massachusetts
• Dana Farber Cancer Institute At St. Elizabeth'S Medical Center — Brighton, Massachusetts
• Dana Farber Brigham Cancer Center — Foxborough, Massachusetts
• Dana Farber At Milford Regional Cancer Center — Milford, Massachusetts
• Dana Farber/Bwcc in Affiliation With South Shore Hospital — South Weymouth, Massachusetts
• Astera Cancer Care — East Brunswick, New Jersey
• Regional Cancer Care Associates LLC — Hackensack, New Jersey

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Metastatic Non Small Cell Lung Cancer

• Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation — Cerritos, California
• Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations — Chandler, Arizona
• Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC) — St Louis, Missouri
• Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer — Gilbert, Arizona
• MOv19-BBz CAR T Cells in FRa+ Cancers — Philadelphia, Pennsylvania

Explore by condition: All Metastatic Non Small Cell Lung Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.